Citi Upgrades ZymoGenetics (ZGEN) to Hold
ZGEN Hot Sheet
Rating Summary:1 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Citi upgrades ZymoGenetics (Nasdaq: ZGEN) from Sell to Hold. Price target $9.
Citi analyst says, "While we view ZymoGenetics' rhThrombin as best-in class, we believe the Street may be overestimating the market opportunity for rhThrombin, and therefore, we believe the sales of the product are likely to be below Street expectation upon launch in early 2008. We expect the thrombin market to become competitive. JNJ's Ethicon division has one of the strongest presence in the operating room market. While we believe ZGEN is overvalued based on rhThrombin and its target market size, in the short term we believe ZGEN will remain in a trading range given few near-term catalysts."
ZymoGenetics, Inc. is focused on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human diseases.
Citi analyst says, "While we view ZymoGenetics' rhThrombin as best-in class, we believe the Street may be overestimating the market opportunity for rhThrombin, and therefore, we believe the sales of the product are likely to be below Street expectation upon launch in early 2008. We expect the thrombin market to become competitive. JNJ's Ethicon division has one of the strongest presence in the operating room market. While we believe ZGEN is overvalued based on rhThrombin and its target market size, in the short term we believe ZGEN will remain in a trading range given few near-term catalysts."
ZymoGenetics, Inc. is focused on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human diseases.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Goldman Sachs Cuts Numbers on Tiffany & Co. (TIF) after Weak Q1, Guidance
- Wells Fargo Upgrades Aeropostale, Inc. (ARO) to Market Perform; Risk/Reward Even Given Improving Trends
Create E-mail Alert Related Categories
UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
